Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.
The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211939
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Issuance of common stock under the ATM offering program, net of issuance costs | 9,810 | — |
| Net cash provided by financing activities | 11,484 | — |
| Net increase (decrease) in cash and cash equivalents | 12,247 | (15,810) |
| Cash and cash equivalents, beginning of period | 60,241 | 149,336 |
| Cash and cash equivalents, end of period | $72,488 | $133,526 |
| Supplemental disclosures of noncash investing and financing information | ||
| Purchases of property and equipment in accounts payable and accrued and other liabilities | — | $140 |
| Unpaid costs from ATM offering program in accrued and other current liabilities | $98 | — |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is 4D Molecular Therapeutics's capex?
- 4D Molecular Therapeutics (FDMT) reported capex of $0 in Q1 2026.
- How has 4D Molecular Therapeutics's capex changed year-over-year?
- 4D Molecular Therapeutics's capex decreased by 100.0% year-over-year, from $631K to $0.
- What is the long-term trend for 4D Molecular Therapeutics's capex?
- Over 3 years (2021 to 2024), 4D Molecular Therapeutics's capex has grown at a -25.4% compound annual growth rate (CAGR), from $9.11M to $3.79M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about 4D Molecular Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude